MDS, the Toronto-based parent company of Canadian medical isotope supplier MDS Nordion, reported that its Life Sciences division, which includes MDS Nordion, had fiscal 2003 third-quarter revenues of $279 million, Canadian ($203.3 million, U.S.) up 4% from $269 million, CAD ($195.9 million) for the same period in 2002.
For the quarter (end-July 31), operating income for the Life Sciences segment was $56 million, CAD ($40.8 million), up 8% compared with $52 million, CAD ($37.9 million) in the third quarter of 2002.
The firm added that despite lower revenue growth in both its isotopes and pharmaceutical research services businesses, the operating margin in the segment was 20% in the current quarter, compared with the 19% realized last year. Excluding the Oncology Software Solutions and the high-dose-rate brachytherapy businesses, which were sold in prior periods, Life Sciences revenues grew by 9% during the third quarter, compared to the same period last year, according to the company
By AuntMinnie.com staff writersSeptember 4, 2003
Related Reading
MDS Nordion inks licensing deal, August 12, 2003
MDS Nordion brings new cyclotron online, June 17, 2003
MDS sells oncology software unit to Delft, February 11, 2003
MDS Nordion gets regulatory approvals, July 11, 2002
MDS Nordion focuses on oncology software solutions, June 28, 2002
Copyright © 2003 AuntMinnie.com
